P. Souquet

B. Milleron, S. Lantuejoul, G. Zalcman, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

IFCT0401 trial: Phase II study of gefitinib administered as first-line treatment in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC): Final results on efficacy and survival

B. Milleron, J. Soria, D. Moro-Sibilot, 2007 .

Cancers thoraciques - ASCO 2009

P. Souquet, 2009 .

IFCT0401-bio trial: Predictive biological markers for disease control (DC) of patients with non-resectable, adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC) treated with gefitinib

G. Zalcman, F. Coulet, P. Souquet, 2007 .

Lessons from the ‘Iressa’ Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations

A. Rossi, C. Gridelli, R. Stahel, 2003, British Journal of Cancer.

LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928)

M. Socinski, E. Smit, Gregory Riely, 2014 .

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

O. Molinier, J. Pujol, M. Denis, 2020, Journal of clinical medicine.

Bronchial mucous gland adenoma revealed following acute pneumonia.

P. Souquet, S. Couraud, S. Isaac, 2012, Interactive cardiovascular and thoracic surgery.

Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE.

O. Molinier, G. Zalcman, P. Dumont, 2016 .

[Management and outcome of French elderly patients with lung cancer: an IFCT survey].

B. Milleron, P. Souquet, P. Girard, 2010, Revue des maladies respiratoires.

Tobacco use and related behaviors among staff and students in a university hospital: A large cross-sectional survey

P. Souquet, P. Michel, J. Fassier, 2021, Tobacco prevention & cessation.

Primary lung adenocarcinoma occurring in a PTEN related syndrome (Cowden's disease): routine EGFR sequencing also highlights two rare somatic mutations S768I and V769L.

I. Durieu, P. Souquet, A. Boespflug, 2013, Lung cancer.

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)

E. Quoix, B. Mennecier, G. R. Ferretti, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Presentation, Diagnosis, and Bacterial Epidemiology of Peritoneal Tuberculosis in Two University Hospitals in France

P. Vanhems, L. Boussel, G. Lina, 2016, Infectious Diseases and Therapy.

B. Milleron, O. Molinier, G. Zalcman, 2016, European Respiratory Journal.

Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?

G. Lina, G. Catho, P. Souquet, 2015, Open forum infectious diseases.

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

C. Dumontet, O. Trédan, P. Souquet, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[Association of mycosis fungoides and Hodgkin's disease].

B. Coiffier, P. Souquet, J. Thivolet, 1984, Annales de dermatologie et de venereologie.

Professional practice and accessibility to equipment in thoracic oncology. Results of a survey in Rhônes-Alpes region (France).

D. Moro-Sibilot, P. Souquet, P. Fournel, 2011, Bulletin du cancer.

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes

S. Dalle, P. Souquet, A. Boespflug, 2021, Cancers.

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.

H. Groen, T. Overbeck, Michael Thomas, 2020, The New England journal of medicine.

Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.

S. Dalle, P. Souquet, D. Fouque, 2021, European journal of cancer.

A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer.

B. Croisile, P. Souquet, J. Bérille, 1996, European journal of cancer.

Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.

H. Groen, E. Smit, R. Heist, 2019, Journal of Clinical Oncology.

Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.

H. Groen, M. Socinski, E. Smit, 2017 .

[Chronic necrotizing pulmonary aspergillosis following an infection by Mycobacterium malmoense].

P. Souquet, A. Boibieux, V. Avrillon, 2012, Revue des maladies respiratoires.

Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.

P. Souquet, P. Fournel, G. Chatté, 1996, Seminars in oncology.

Sequential versus concurrent chemo-radiation (RT-CT) in locally advanced non small cell lung cancer (NSCLC): A French randomized phase III trial of GLOT-GFPC (NPC 95-01 study)

J. Daurès, P. Souquet, P. Fournel, 2001 .

CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients.

G. Deplanque, C. Robert, O. Chosidow, 2010 .

Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.

P. Souquet, D. Damotte, C. Chouaid, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Hodgkin's disease associated with IgA and IgG subclass deficiency

C. Cunningham-Rundles, P. Souquet, T. Zénone, 1996, Journal of internal medicine.

Earlier Onset and Poor Prognosis of Lung Cancer in Imprisoned Patients

P. Chossegros, P. Souquet, M. Carbonnaux, 2013, Oncology.

[Agenesis of the pericardium: clinical, echocardiographic and MRI aspects].

J. Mallet, P. Souquet, J. Bernard, 1988, Revue de pneumologie clinique.

Existent-ils des contre-indications à l’immunothérapie dans les cancers broncho-pulmonaires ?

M. Darrason, P. Souquet, N. Freymond, 2020 .

Completion Pneumonectomy in Patients with Cancer: Postoperative Survival and Mortality Factors

P. Souquet, S. Couraud, F. Tronc, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The prognostic value of etoposide area under the curve (AUC) at first chemotherapy cycle in small cell lung cancer patients: a multicenter study of the groupe Lyon-Saint-Etienne d'Oncologie Thoracique (GLOT).

E. Morignat, I. Court-Fortune, P. Souquet, 2001, Lung cancer.

Immune checkpoint inhibitors: a game changer for metastatic non-small-cell lung cancer.

P. Souquet, S. Couraud, 2019, The Lancet. Oncology.

IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC.

N. Girard, O. Molinier, J. Mazières, 2017 .

Is Nutritional Screening of Patients with Lung Cancer Optimal? An Expert Opinion Survey of French Physicians and Surgeons

P. Souquet, S. Couraud, J. Péron, 2019, Nutrition and cancer.

[Exsudative pleurisy revealing an infected aneurysm of the abdominal aorta].

P. Souquet, K. Bouledrak, L. Gérinière, 2010, Revue des maladies respiratoires.

Rhabdomyosarcoma arising in mediastinal teratoma in an adult man: a case report.

J. Droz, P. Souquet, C. Khouatra, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer.

J. Mackey, C. Cass, C. Dumontet, 2005, Lung cancer.

EPICC study: evaluation of pharmaceutical intervention in cancer care

C. Rioufol, P. Souquet, G. Freyer, 2015, Journal of clinical pharmacy and therapeutics.

[Pulmonary histoplasmosis due to Histoplasma capsulatum. A case].

P. Souquet, M. Piens, A. Voloch, 1991, Revue des maladies respiratoires.

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

B. Milleron, O. Molinier, S. Laporte, 2011, The Lancet.

Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy

C. Dumontet, O. Trédan, P. Souquet, 2005, Clinical Cancer Research.

Relationship between food behavior and taste and smell alterations in cancer patients undergoing chemotherapy: A structured review.

M. Bensafi, A. Giboreau, A. Dougkas, 2019, Seminars in oncology.

Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.

C. Rudin, M. Socinski, Gregory Riely, 2013 .

On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.

E. Brambilla, S. Lantuejoul, J. Sabourin, 2014, Lung cancer.

PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.

H. Blons, J. Merlio, F. Escande, 2020, Lung cancer.

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

H. Blanché, J. Trédaniel, G. Zalcman, 2015, European Respiratory Journal.

Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).

N. Girard, E. Brambilla, J. Timsit, 2014, Lung cancer.

Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial

J. Pignon, B. Milleron, J. Soria, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A Randomized Non‐Comparative Phase II Study of Anti‐Programmed Cell Death‐Ligand 1 Atezolizumab or Chemotherapy as Second‐Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT‐1603 Trial

O. Molinier, J. Pujol, M. Denis, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Routine EGFR Molecular Analysis in Non-Small-Cell Lung Cancer Patients is Feasible: Exons 18–21 Sequencing Results of 753 Patients and Subsequent Clinical Outcomes

P. Souquet, P. Bringuier, S. Couraud, 2013, Lung.

IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype

B. Milleron, J. Soria, D. Moro-Sibilot, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.

J. Soria, J. Mazières, G. Zalcman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

No impact of passive smoke on the somatic profile of lung cancers in never-smokers

G. Zalcman, P. Dumont, P. Souquet, 2015, European Respiratory Journal.

Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.

P. Hainaut, E. Brambilla, J. Soria, 2014, Clinical lung cancer.

Intra-Thoracic Chemo-Hyperthermia for pleural recurrence of thymoma.

N. Girard, P. Souquet, C. Leroux, 2017, Lung cancer.

Carcinoma of the colon presenting as pulmonary microabscesses and septicaemia due to Clostridium perfringens.

J. Vergnon, P. Souquet, J. Fleurette, 1984, Thorax.

An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928).

H. Groen, J. Rigas, S. Novello, 2016 .

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

S. Kaasa, P. Ganz, F. Chauvin, 1993, The Lancet.

Mitomycin, Ifosfamide and Platin (MIP) in advanced and disseminated non-small cell lung cancer (NSCLC)

P. Romestaing, P. Souquet, T. Zénone, 1994 .

Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer.

F. Chauvin, P. Souquet, J. Boissel, 1995, Lung cancer.

Biology of Human Tumors Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers : A Proof-of-Concept Study

N. Girard, T. Schuster, M. Olivier, 2014 .

Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002

N. Girard, T. Schuster, M. Olivier, 2014, Clinical Cancer Research.

Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.

N. Girard, O. Molinier, P. Souquet, 2016, Lung cancer.

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.

J. Blay, G. Ferretti, J. Mazières, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.

J. Mosser, D. Planchard, J. Merlio, 2019, European journal of cancer.

The role of chemotherapy in early stage of non-small cell lung cancer.

P. Souquet, L. Gérinière, 2001, Lung cancer.

Inequalities in lung cancer: a world of EGFR

A. Meert, P. Souquet, A. Scherpereel, 2016, European Respiratory Journal.

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

G. Ferretti, G. Vassal, J. Mazières, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study)

I. Durand-zaleski, P. Chauvin, P. Souquet, 2017, PloS one.

Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).

O. Molinier, J. Mazières, G. Zalcman, 2015, Lung cancer.

Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study.

P. Souquet, R. Corre, G. Robinet, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Bone metastases from lung cancer: A paradigm for multidisciplinary onco-rheumatology management.

N. Girard, M. Brevet, P. Souquet, 2019, Joint, bone, spine : revue du rhumatisme.

Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial.

J. Pujol, G. Zalcman, D. Moro-Sibilot, 2014 .

Induction (ICT) or consolidation chemotherapy (CT) with cisplatin (C) and paclitaxel (P) plus concurrent chemo-radiation (CT/TRT) with cisplatin and vinorelbine (V) for unresectable non-small cell lung cancer (NSCLC) patients (pts): Randomized phase II trial GFPC-GLOT-IFCT 02-01.

P. Souquet, P. Fournel, C. Chouaid, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study.

J. Daurès, P. Souquet, P. Fournel, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC).

H. Groen, E. Smit, R. Heist, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination IL-2 and cisplatinum: a promising treatment for bronchioloalveolar carcinoma?

P. Souquet, J. Cordier, A. Mercatello, 1993, European journal of cancer.

Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.

N. Girard, P. Souquet, P. Bringuier, 2016, Lung cancer.

Cisplatin Administration at Outpatient Clinics is Safe Compared to the In-Patient Usual Protocol: Findings from a Comparative Study

D. Moro-Sibilot, P. Souquet, E. Villar, 2015 .

Lung cancer may increase serum procalcitonin level.

P. Souquet, M. Carbonnaux, S. Couraud, 2015, Infectious disorders drug targets.

Negative Predictive Value of Transthoracic Core-Needle Biopsy: A Multicenter Study.

G. Ferretti, P. Souquet, S. Couraud, 2015, Chest.

Clearing obstructed totally implantable central venous access ports

P. Souquet, S. Couraud, S. Muguet, 2012, Supportive Care in Cancer.

[Long-term results of lung cancer surgery in octogenarians].

A. Tchalla, P. Souquet, F. Tronc, 2016, Revue de pneumologie clinique.

Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study

F. Barlesi, P. Souquet, P. Fournel, 2007, Targeted Oncology.

Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study

N. Girard, G. Ferretti, E. Brambilla, 2014, BMC Cancer.

Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.

E. Lemarié, B. Milleron, D. Spaeth, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment

D. Planchard, P. Souquet, F. Bonnetain, 2019, Journal of cachexia, sarcopenia and muscle.

Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer.

N. Girard, P. Souquet, F. Mornex, 2009, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Circulating free DNA concentration is an independent prognostic biomarker in lung cancer

J. Zavadil, M. Olivier, S. Villar, 2015, European Respiratory Journal.

Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.

O. Molinier, J. Pujol, P. Dumont, 2020, European journal of cancer.

Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504

G. Zalcman, D. Moro-Sibilot, F. Barlesi, 2015, European Respiratory Journal.

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer

B. Milleron, O. Molinier, J. Trédaniel, 2013, European Respiratory Journal.

Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors

C. Lombard-Bohas, P. Souquet, M. Carbonnaux, 2014, Investigational new drugs.

[Pneumocystis carinii pneumonia in a patient without any sign of immunodeficiency].

P. Souquet, A. Voloch, J. Bernard, 1992, Presse medicale.

Preoperative chemotherapy does not increase complications after nonsmall cell lung cancer resection.

P. Souquet, I. Arnaud, P. Roy, 2005, The Annals of thoracic surgery.

1273OResults of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)

E. Devin, J. Lafitte, J. Trédaniel, 2017 .

Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.

J. Daurès, P. Souquet, P. Fournel, 2016, European journal of cancer.

Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01).

C. Combescure, P. Souquet, P. Fournel, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non small cell lung cancer (NSCLC). Interim analysis of toxicity. (GLOT-GFPC NPC 95-01 study)

J. Daurès, P. Souquet, P. Fournel, 2000 .

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

G. Ferretti, G. Vassal, J. Mazières, 2019 .

Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).

B. Milleron, G. Zalcman, D. Moro-Sibilot, 2010, Lung cancer.

Physicians' knowledge and practice of lung cancer screening: a cross-sectional survey comparing general practitioners, thoracic oncologists, and pulmonologists in France.

N. Girard, F. Gueyffier, P. Souquet, 2013, Clinical lung cancer.

[Value of C-reactive protein determination in small cell lung cancer].

P. Souquet, C. Lasset, J. Cordier, 1993, Bulletin du cancer.

[Single French centre retrospective analysis of local control after high dose radiotherapy with or without chemotherapy and local control for Pancoast tumours].

B. De Bari, P. Souquet, F. Mornex, 2012, Cancer Radiothérapie.

Acute Respiratory Failure in Obesity-Hypoventilation Syndrome Managed in the ICU

T. Rimmele, L. Argaud, P. Souquet, 2019, Respiratory Care.

Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study

I. Durand-zaleski, P. Chauvin, P. Souquet, 2018, BMC Cancer.

Is Pneumonectomy After Induction Chemotherapy for Non-small Cell Lung Cancer a Reasonable Procedure? A Multicenter Retrospective Study of 228 Cases

P. Souquet, L. Remontet, J. Baulieux, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer.

M. Krzakowski, R. Ramlau, R. Rosell, 2010, Clinical lung cancer.

Abstract CT082: Capmatinib inMETex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRYmono-1study, including efficacy in patients (pts) with brain metastases (BM)

H. Groen, E. Smit, R. Heist, 2020 .

Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.

H. Groen, A. Mansfield, E. Smit, 2020 .

GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients.

R. V. van Klaveren, U. Gatzemeier, A. Price, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Is transthoracic core needle biopsy under CT scan a good deal for benign diseases' diagnosis?

G. Ferretti, P. Souquet, E. Pradat, 2014 .

Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel

J. Mackey, C. Dumontet, O. Trédan, 2005, Molecular Cancer Therapeutics.

[Paraneoplastic intestinal pseudo-occlusion and sensory neuronopathy disclosing small-cell bronchial cancer].

P. Souquet, J. Pasquier, P. Gonnaud, 1997, La Revue de medecine interne.

Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors.

D. Planchard, E. Baudin, V. Hervieu, 2016, Lung cancer.

[Clinical and economic evaluation of the initial assessment of small cell cancer of the lung. Alternatives to classic evaluation. LGTO. The Lyon Group of Thoracic Oncology].

I. Court-Fortune, F. Chauvin, P. Souquet, 1993, Revue des maladies respiratoires.

[Lung cancer in never smokers: a French national cohort (BioCAST/IFCT-1002)].

H. Blanché, B. Milleron, G. Zalcman, 2013, Revue des maladies respiratoires.

Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial.

P. Souquet, P. Fournel, H. Léna, 2002, Lung cancer.

1273P Durvalumab (D) compared to maintenance chemotherapy (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the randomized SAFIR02 LUNG-IMMUNO trial

I. Bièche, J. Adam, J. Soria, 2020 .

Administration of anticancer drugs: exposure in hospital nurses.

C. Rioufol, P. Souquet, J. Guitton, 2014, Clinical Therapeutics.

Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases.

N. Girard, J. Honnorat, V. Cottin, 2006, Lung cancer.

Polychemotherapy in advanced non-small-cell lung cancer

A. Rodger, P. Souquet, T. Maughan, 1993, The Lancet.

Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting.

G. Lina, G. Catho, P. Souquet, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

82 Treatment of advanced and disseminated non small lung cancer (NSCLC) in elderly patients: Results of the MIC regimen

P. Souquet, P. Bombaron, J. Bernard, 1997 .

[Standards, options and recommendations for the management of locally advanced non small cell lung carcinoma].

E. Touboul, E. Lemarié, B. Milleron, 2001, Bulletin du cancer.

[Malignant mesothelioma of the pleura following radiotherapy of Hodgkin disease].

B. Coiffier, P. Souquet, L. Falchero, 1996, Bulletin du Cancer.

Are clinical guidelines applied in routine daily practice?: a French regional survey of physicians' clinical practices in lung cancer management (EPOTRA).

D. Moro-Sibilot, P. Souquet, P. Fournel, 2011, Clinical lung cancer.

[Paclitaxel-bevacizumab is a possible alternative as salvage chemotherapy in advanced non-small cell bronchial carcinoma].

D. Moro-Sibilot, P. Souquet, S. Couraud, 2014, Revue des maladies respiratoires.

Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703.

J. Pignon, B. Milleron, J. Soria, 2015 .

OA11.01 Prolonged OS of Patients Exposed to Weekly Paclitaxel and Bevacizumab: Impact of the Cross-Over in the IFCT-1103 ULTIMATE Study

O. Molinier, G. Zalcman, P. Dumont, 2017 .

Bronchial mucous gland adenoma revealed following acute pneumonia.

P. Souquet, S. Couraud, S. Isaac, 2012, Interactive cardiovascular and thoracic surgery.

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

F. Cappuzzo, D. Gandara, D. Planchard, 2015, The Lancet. Oncology.

Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients.

S. Lantuejoul, I. Ray-Coquard, F. de Fraipont, 2019, Future oncology.

A randomized non-comparative phase II study of anti-PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial.

L. Thiberville, O. Molinier, J. Mazières, 2018, Annals of Oncology.

Implementing flexible bronchoscopy in least developed countries according to international guidelines is feasible and sustainable: example from Phnom-Penh, Cambodia

P. Souquet, S. Couraud, V. Avrillon, 2017, BMC Pulmonary Medicine.

Is Pneumonectomy After Induction Chemotherapy for Non-small Cell Lung Cancer a Reasonable Procedure? A Multicenter Retrospective Study of 228 Cases

P. Souquet, L. Remontet, J. Baulieux, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.